Pharmanema SRL
Pharmanema reported total assets of 910,021 € at the end of the 2025 financial year (annual accounts filed with the NBB on 07 Jul 2026).
The score of Pharmanema shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +27 % Total assets +38 %
Accounts of the company itself (not consolidated).
The full file covers 12 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Pharmanema's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 35,668 € | ||||
| Equity | 357,607 € | ||||
| Cash | 95,893 € | ||||
| EBITDA | 112,133 € | ||||
| Total assets | 910,021 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 07 Jul 2026
- Year ended 31 Dec 2024filed on 11 Jul 2025
- Year ended 31 Dec 2023filed on 05 Jul 2024
- Year ended 31 Dec 2022filed on 01 Jun 2023
- Year ended 31 Dec 2021filed on 16 Jun 2022
Pharmanema's financial analysis
- Solvency39.3%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Pharmanema
Pharmanema's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0479.052.415
- VAT number
- BE0479052415
- Peppol
- Registered · 0208:0479052415 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 23 Dec 2002
- Registered office
- 3012 Leuven
- Latest accounts
- 2025 · filed on 07 Jul 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Pharmanema (SRL) has been based in Leuven since 2002, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 35,668 € and equity of 357,607 €; its revenue is not published. Its solvency stands at 39.3%, below the median of its sector (44.2%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Pharmanema
Companies in the same business, of comparable size and area, outside its group.
- Pharmuny Retail sale of pharmaceutical products Ellezelles · balance sheet 909,631 €
- Apotheek van Besien Retail sale of pharmaceutical products Nieuwpoort · balance sheet 909,462 €
- Novil'Pharma Retail sale of pharmaceutical products Fernelmont · balance sheet 907,966 €
- Pharmacie des Câbleries Retail sale of pharmaceutical products Dour · balance sheet 907,567 €
- Pharma Tilleul Retail sale of pharmaceutical products Montigny-le-Tilleul · balance sheet 912,565 €
- Propharma Retail sale of pharmaceutical products Ottignies-Louvain-la-Neuve · balance sheet 915,541 €
- Holsbeek Deurne Retail sale of pharmaceutical products Antwerp · balance sheet 917,585 €
- COX Retail sale of pharmaceutical products Hasselt · balance sheet 917,941 €
Frequently asked questions about Pharmanema
What is the revenue of Pharmanema?
Pharmanema files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Pharmanema?
In Belgium, the VAT number is the company number prefixed with BE: BE0479052415 for Pharmanema, if the company is VAT-registered. Its company number (CBE) is 0479.052.415.
Where is the registered office of Pharmanema?
According to the CBE register, the registered office of Pharmanema is in 3012 Leuven.
What is the equity of Pharmanema?
At the close of the 2025 financial year, the equity of Pharmanema amounts to 357,607 €, a solvency of 39.3% of total assets.
Who manages Pharmanema?
The register lists 2 active mandates at Pharmanema. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Pharmanema
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →